Literature DB >> 28972957

Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion.

Monika Gawałko, Agnieszka Kapłon-Cieślicka, Monika Budnik, Aldona Babiarz, Aleksandra Bodys, Robert Uliński, Maciej Żochowski, Michał Peller, Piotr Scisło, Janusz Kochanowski, Krzysztof J Filipiak, Grzegorz Opolski.   

Abstract

INTRODUCTION    Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative to vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF). OBJECTIVES    The aim of the study was to assess the incidence of left atrial appendage (LAA) thrombus and dense spontaneous echo contrast (SEC), as well as to compare the clinical characteristics of patients with AF treated with different anticoagulant regimens. PATIENTS AND METHODS    We studied 1033 consecutive patients with AF, who underwent transesophageal echocardiography (TEE) before AF ablation or cardioversion. We excluded 174 patients without any prior oral anticoagulation or who underwent bridging with heparin before TEE. RESULTS    In the study group of 859 patients (median age, 61 years; men, 66%), 437 patients (50.9%) received VKAs; 191 (22.2%), dabigatran; 230 (26.8%), rivaroxaban; and 1 patient (0.1%), apixaban. There were no differences in baseline characteristics or the incidence of LAA thrombus (VKAs, 6.9%; NOACs, 5.5%; P = 0.40) and dense SEC (VKAs, 5.3%; NOACs, 3.3%; P = 0.18) between patients on VKAs and those on NOACs. Compared with patients treated with dabigatran, those on rivaroxaban more often had paroxysmal AF, higher ejection fraction, LAA emptying velocity, and platelet count, as well as lower left ventricular end‑diastolic dimension and hematocrit. The frequency of LAA thrombus in patients receiving dabigatran and those receiving rivaroxaban was comparable (6.8% vs 4.4%; P = 0.29), while dense SEC occurred more often in patients treated with dabigatran (5.2% vs 1.7%; P = 0.06). In a logistic regression analysis, none of the oral anticoagulation regimens predicted LAA thrombus in TEE, whereas maximal LAA emptying velocity was the only parameter independently associated with the presence of thrombus. CONCLUSIONS    In the studied group of patients with AF, the choice of anticoagulation did not depend on thromboembolic or bleeding risk.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28972957     DOI: 10.20452/pamw.4117

Source DB:  PubMed          Journal:  Pol Arch Intern Med        ISSN: 0032-3772


  6 in total

1.  Left Atrial Thrombus in Atrial Fibrillation/Flutter Patients in Relation to Anticoagulation Strategy: LATTEE Registry.

Authors:  Agnieszka Kapłon-Cieślicka; Monika Gawałko; Monika Budnik; Beata Uziębło-Życzkowska; Paweł Krzesiński; Katarzyna Starzyk; Iwona Gorczyca-Głowacka; Ludmiła Daniłowicz-Szymanowicz; Damian Kaufmann; Maciej Wójcik; Robert Błaszczyk; Jarosław Hiczkiewicz; Katarzyna Łojewska; Katarzyna Mizia-Stec; Maciej T Wybraniec; Katarzyna Kosmalska; Marcin Fijałkowski; Anna Szymańska; Mirosław Dłużniewski; Maciej Haberka; Michał Kucio; Błażej Michalski; Karolina Kupczyńska; Anna Tomaszuk-Kazberuk; Katarzyna Wilk-Śledziewska; Renata Wachnicka-Truty; Marek Koziński; Paweł Burchardt; Piotr Scisło; Radosław Piątkowski; Janusz Kochanowski; Grzegorz Opolski; Marcin Grabowski
Journal:  J Clin Med       Date:  2022-05-11       Impact factor: 4.964

2.  Clinical characteristics and thromboembolic risk of atrial fibrillation patients with and without congestive heart failure. Results from the CRATF study.

Authors:  Paweł Balsam; Monika Gawałko; Michał Peller; Agata Tymińska; Krzysztof Ozierański; Martyna Zaleska; Katarzyna Żukowska; Katarzyna Szepietowska; Kacper Maciejewski; Marcin Grabowski; Mariusz Borkowski; Łukasz Kołtowski; Anna Praska-Oginska; Inna Zaboyska; Grzegorz Opolski; Janusz Bednarski
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

Review 3.  Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion.

Authors:  Bruce A Warden; John MacKay; Melika Jafari; Alana Willman; Eric C Stecker
Journal:  J Am Heart Assoc       Date:  2018-11-20       Impact factor: 5.501

4.  Comparison of transesophageal echocardiography findings after different anticoagulation strategies in patients with atrial fibrillation: a systematic review and meta-analysis.

Authors:  Jian Yang; Xuan Zhang; Xi-Ying Wang; Chi Zhang; Song-Zan Chen; Shen-Jiang Hu
Journal:  BMC Cardiovasc Disord       Date:  2019-11-26       Impact factor: 2.298

5.  Left Ventricular Ejection Fraction Is Associated with the Risk of Thrombus in the Left Atrial Appendage in Patients with Atrial Fibrillation.

Authors:  Beata Uziębło-Życzkowska; Paweł Krzesiński; Agnieszka Jurek; Agnieszka Kapłon-Cieślicka; Iwona Gorczyca; Monika Budnik; Grzegorz Gielerak; Marek Kiliszek; Monika Gawałko; Piotr Scisło; Janusz Kochanowski; Olga Jelonek; Anna Michalska; Katarzyna Starzyk; Krzysztof J Filipiak; Beata Wożakowska-Kapłon; Grzegorz Opolski
Journal:  Cardiovasc Ther       Date:  2020-04-24       Impact factor: 3.023

6.  Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease.

Authors:  Monika Budnik; Monika Gawałko; Iwona Gorczyca; Beata Uziębło-Życzkowska; Paweł Krzesiński; Janusz Kochanowski; Piotr Scisło; Anna Michalska; Olga Jelonek; Katarzyna Starzyk; Agnieszka Jurek; Marek Kiliszek; Beata Wożakowska-Kapłon; Grzegorz Gielerak; Krzysztof J Filipiak; Grzegorz Opolski; Agnieszka Kapłon-Cieślicka
Journal:  Cardiol J       Date:  2020-03-24       Impact factor: 2.737

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.